Indefinite Delivery Contract HHSN261201500026I
Award Date
9/22/15
Last Date to Order
9/24/18
Federal Agency
National Cancer Institute
Awardee
University Of Illinois
Ultimate Awardee
University Of Illinois
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The University of Illinois, through The Board of Trustees of the University of Illinois, holds an Indefinite Delivery Indefinite Quantity (IDIQ) contract from the National Cancer Institute (NCI) to support the PREVENT Cancer Preclinical Drug Development Program. This $149,995,000 multiple-award contract aims to provide a structured approach to the development of cancer drugs and vaccines from discovery through clinical trials. The contract includes three separate pools: evaluating the efficacy...
The University of Illinois, doing business as The Board of Trustees of the University of Illinois, was awarded an Indefinite Delivery Contract (IDC) valued at $149,995,000 from the National Cancer Institute (NCI) to support the PREVENT Cancer Preclinical Drug Development Program. This multiple-award contract aims to provide a structured approach to the development of cancer drugs and vaccines from discovery through clinical trials. The contract is divided into three separate pools: evaluating...
The University of Illinois, doing business as The Board of Trustees of the University of Illinois, has been awarded an Indefinite Delivery Contract (IDC) from the National Cancer Institute (NCI), a part of the U.S. Department of Health and Human Services, to support the PREVENT Cancer Preclinical Drug Development Program. This multiple-award IDC, valued at up to $149,995,000, aims to provide a structured approach to the development of cancer drugs and vaccines from discovery through clinical...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...
The National Cancer Institute (NCI) awarded a $74,995,000 multiple-award indefinite delivery/indefinite quantity (IDIQ) contract called the PREVENT Preclinical Drug Development Program to support preclinical pharmacology, toxicology, and product development services for cancer therapy candidates. The prime contractor, IIT Research Institute (IITRI), is a non-profit division of the Illinois Institute of Technology that specializes in these preclinical services for federal agencies. Under this...
This federal indefinite delivery contract was awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the non-profit IIT Research Institute (IITRI). The $19 million PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) IDIQ contract vehicle enables NCI to efficiently access IITRI's preclinical research capabilities on an as-needed basis to support the development of cancer prevention therapies. Task orders issued under this...
The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...
The National Cancer Institute (NCI), part of the Department of Health and Human Services, has awarded an Indefinite Delivery Contract (IDC) valued at $29,800,000 to The Institute for Cancer Research, a non-profit subsidiary of Temple University. The contract, titled "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS," has a period of performance from September 22, 2015 to September 21, 2018. Under this multiple-award IDC, The Institute for...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a multiple-award indefinite delivery/indefinite quantity (IDIQ) contract to Weill Medical College of Cornell University to provide preclinical research services for the PREVENT Cancer Preclinical Drug Development Program. Under this $149,995,000 IDIQ, the contractor performs efficacy testing, biomarker evaluation, and analytical assay development to advance cancer...
This is a multiple award Indefinite Delivery Contract (IDC) issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services. The contract has a ceiling value of $9,950,000 and was awarded to the University of Oklahoma (OU) to provide preclinical research and development services related to cancer prevention and treatment. The task orders issued under this IDC cover a range of preclinical oncology research activities, including the evaluation of...